1 Chang, CY, Ke, DS & Chen, JY (2009) Essential fatty acids and human brain. Acta Neurol Taiwan 18, 231–241.
2 Horrobin, D (2002) Cardiovascular disease, affective disorders and impaired fatty acid and phosopholipid metabolism. In Vascular disease and affective disorders, pp. 332–352 [Chiu E, AD and Katona, C, editors]. London: United Kingdom.
3 Young, G & Conquer, J (2005) Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 45, 1–28.
4 Freeman, MP, Hibbeln, JR, Wisner, KL, et al. (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67, 1954–1967.
5 Bourre, JM (2005) Dietary omega-3 Fatty acids and psychiatry: mood, behaviour, stress, depression, dementia and aging. J Nutr Health Aging 9, 31–38.
6 Silvers, KM, Woolley, CC, Hamilton, FC, et al. (2005) Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 72, 211–218.
7 Grenyer, BF, Crowe, T, Meyer, B, et al. (2007) Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31, 1393–1396.
8 Raz, R, Carasso, RL & Yehuda, S (2009) The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 19, 167–177.
9 Appleton, KM, Rogers, PJ & Ness, AR (2010) Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 91, 757–770.
10 Chiu, CC, Huang, SY, Chen, CC, et al. (2005) Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 66, 1613–1614.
11 van de Rest, O, Geleijnse, JM, Kok, FJ, et al. (2008) Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 88, 706–713.
12 Lucas, M, Asselin, G, Merette, C, et al. (2009) Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 89, 641–651.
13 Rondanelli, M, Giacosa, A, Opizzi, A, et al. (2010) Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 29, 55–64.
14 Gracious, BL, Chirieac, MC, Costescu, S, et al. (2010) Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord 12, 142–154.
15 Nemets, H, Nemets, B, Apter, A, et al. (2006) Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 163, 1098–1100.
16 Jazayeri, S, Tehrani-Doost, M, Keshavarz, SA, et al. (2008) Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 42, 192–198.
17 Marangell, LB, Martinez, JM, Zboyan, HA, et al. (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160, 996–998.
18 Mischoulon, D, Best-Popescu, C, Laposata, M, et al. (2008) A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol 18, 639–645.
19 Mischoulon, D, Papakostas, GI, Dording, CM, et al. (2009) A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry 70, 1636–1644.
20 Nemets, B, Stahl, Z & Belmaker, RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159, 477–479.
21 Peet, M & Horrobin, DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59, 913–919.
22 Silvers, KM, Woolley, CC, Hamilton, FC, et al. (2005) Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 72, 211–218.
23 Su, KP, Huang, SY, Chiu, CC, et al. (2003) Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13, 267–271.
24 Frangou, S, Lewis, M & McCrone, P (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188, 46–50.
25 Keck, PE Jr, Mintz, J, McElroy, SL, et al. (2006) Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60, 1020–1022.
26 Stoll, AL, Severus, WE, Freeman, MP, et al. (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56, 407–412.
27 Rogers, PJ, Appleton, KM, Kessler, D, et al. (2008) No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 99, 421–431.
28 Bot, M, Pouwer, F, Assies, J, et al. (2010) Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord 126, 282–286.
29 Carney, RM, Freedland, KE, Rubin, EH, et al. (2009) Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 302, 1651–1657.
30 da Silva, TM, Munhoz, RP, Alvarez, C, et al. (2008) Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 111, 351–359.
31 Freund-Levi, Y, Basun, H, Cederholm, T, et al. (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161–169.
32 Antypa, N, Van der Does, AJ, Smelt, AH, et al. (2009) Omega-3 fatty acids (fish-oil) and depression-related cognition in healthy volunteers. J Psychopharmacol 23, 831–840.
33 Rees, AM, Austin, MP & Parker, GB (2008) Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 42, 199–205.
34 Makrides, M, Gibson, RA, McPhee, AJ, et al. (2010) Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA 304, 1675–1683.
35 Su, KP, Huang, SY, Chiu, TH, et al. (2008) Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69, 644–651.
36 Llorente, AM, Jensen, CL, Voigt, RG, et al. (2003) Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 188, 1348–1353.
37 Doornbos, B, van Goor, SA, Dijck-Brouwer, DA, et al. (2009) Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample. Prog Neuropsychopharmacol Biol Psychiatry 33, 49–52.
38 Freeman, MP, Davis, M, Sinha, P, et al. (2008) Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 110, 142–148.
39 Belanger, SA, Vanasse, M, Spahis, S, et al. (2009) Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. Paediatr Child Health 14, 89–98.
40 Sinn, N & Bryan, J (2007) Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 28, 82–91.
41 Raz, R, Carasso, RL & Yehuda, S (2009) The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 19, 167–177.
42 Voigt, RG, Llorente, AM, Jensen, CL, et al. (2001) A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 139, 189–196.
43 Gustafsson, PA, Birberg-Thornberg, U, Duchen, K, et al. (2010) EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 99, 1540–1549.
44 Johnson, M, Ostlund, S, Fransson, G, et al. (2009) Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 12, 394–401.
45 Hirayama, S, Hamazaki, T & Terasawa, K (2004) Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 58, 467–473.
46 Richardson, AJ & Puri, BK (2002) A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 26, 233–239.
47 Olfson, M, Shea, S, Feder, A, et al. (2000) Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 9, 876–883.
48 McIntyre, RS & O'Donovan, C (2004) The human cost of not achieving full remission in depression. Can J Psychiatry 49, 10S–16S.
49 Lin, PY & Su, KP (2007) A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 68, 1056–1061.
50 Pouwer, F, Nijpels, G, Beekman, AT, et al. (2005) Fat food for a bad mood. Could we treat and prevent depression in Type 2 diabetes by means of omega-3 polyunsaturated fatty acids? A review of the evidence. Diabet Med 22, 1465–1475.
51 Martins, JG (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28, 525–542.
52 Hegarty, BD & Parker, GB (2011) Marine omega-3 fatty acids and mood disorders - linking the sea and the soul: 'Food for Thought' I. Acta Psychiatr Scand 124, 42–51.
53 Lustman, PJ & Clouse, RE (2002) Treatment of depression in diabetes: impact on mood and medical outcome. J Psychosom Res 53, 917–924.
54 Nuyen, J, Schellevis, FG, Satariano, WA, et al. (2006) Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol 59, 1274–1284.
55 Wichowicz, HM, Slawek, J, Derejko, M, et al. (2006) Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. Eur Psychiatry 21, 516–520.
56 Vajda, FJ & Solinas, C (2005) Current approaches to management of depression in Parkinson's Disease. J Clin Neurosci 12, 739–743.
57 McKeith, I & Cummings, J (2005) Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 4, 735–742.
58 Al, MD, van Houwelingen, AC & Hornstra, G (2000) Long-chain polyunsaturated fatty acids, pregnancy, and pregnancy outcome. Am J Clin Nutr 71, 285S–291S.
59 Jans, LA, Giltay, EJ & Van der Does, AJ (2010) The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression. Br J Nutr 104, 1577–1585.
60 Walsh, BT, Seidman, SN, Sysko, R, et al. (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287, 1840–1847.
61 Colquhoun, I & Bunday, S (1981) A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses 7, 673–679.
62 Stevens, L, Zhang, W, Peck, L, et al. (2003) EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 38, 1007–1021.
63 Mitchell, EA, Aman, MG, Turbott, SH, et al. (1987) Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 26, 406–411.
64 Arnold, LE, Kleykamp, D, Votolato, NA, et al. (1989) Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry 25, 222–228.
65 Burgess, JR, Stevens, L, Zhang, W, et al. (2000) Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 71, 327S–330S.
66 Chen, JR, Hsu, SF, Hsu, CD, et al. (2004) Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 15, 467–472.
67 Raz, R & Gabis, L (2009) Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 51, 580–592.
68 Zanarini, MC & Frankenburg, FR (2003) Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160, 167–169.
69 Fux, M, Benjamin, J & Nemets, B (2004) A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 38, 323–325.
70 Richardson, AJ & Montgomery, P (2005) The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 115, 1360–1366.